CN109329930A - A kind of composition and preparation method thereof for promoting uric acid to reduce - Google Patents
A kind of composition and preparation method thereof for promoting uric acid to reduce Download PDFInfo
- Publication number
- CN109329930A CN109329930A CN201811300601.9A CN201811300601A CN109329930A CN 109329930 A CN109329930 A CN 109329930A CN 201811300601 A CN201811300601 A CN 201811300601A CN 109329930 A CN109329930 A CN 109329930A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- composition
- reduce
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 72
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229940116269 uric acid Drugs 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 230000001737 promoting effect Effects 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 43
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 20
- 244000197580 Poria cocos Species 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 102000016942 Elastin Human genes 0.000 claims abstract description 13
- 108010014258 Elastin Proteins 0.000 claims abstract description 13
- 229920002549 elastin Polymers 0.000 claims abstract description 13
- 244000046146 Pueraria lobata Species 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 229920001202 Inulin Polymers 0.000 claims description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 8
- 229940029339 inulin Drugs 0.000 claims description 8
- 235000008939 whole milk Nutrition 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- 244000017020 Ipomoea batatas Species 0.000 claims description 5
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 235000006468 Thea sinensis Nutrition 0.000 claims description 5
- 238000007605 air drying Methods 0.000 claims description 5
- 235000020279 black tea Nutrition 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 241000269849 Thunnus Species 0.000 claims 1
- 241001251949 Xanthium sibiricum Species 0.000 claims 1
- 240000008866 Ziziphus nummularia Species 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000029142 excretion Effects 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 8
- 230000004144 purine metabolism Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 241000219781 Pueraria montana var. lobata Species 0.000 abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- -1 kalium ion Chemical class 0.000 description 5
- 244000077995 Coix lacryma jobi Species 0.000 description 4
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- ZWSNUPOSLDAWJS-QNDFHXLGSA-N 6,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound OC[C@H]1O[C@@H](Oc2ccc(cc2)-c2coc3cc(O)c(O)cc3c2=O)[C@H](O)[C@@H](O)[C@@H]1O ZWSNUPOSLDAWJS-QNDFHXLGSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150104214 HGPRT gene Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010038481 Renal necrosis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000012642 Sexual Trauma Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of compositions that promotion uric acid reduces, including following components by weight: 10-25 parts of Poria cocos, 10-25 parts of semen coicis, 10-20 parts of pueraria lobatas, the luxuriant Cillium of 7-14 parts of circles, 8-16 parts of odd sub- seed powder, 0.5-3 parts of stripped tuna elastin laminins and the auxiliary material for supplying 100 parts.The composition from reduce blood pressure and blood lipoid and cholesterol, promote uric acid excretion, promote body ion metabolism balance, promote purine metabolism balance etc. it is a variety of in terms of concertedness act on, to combine the generation for inhibiting uric acid and the excretion for improving uric acid, to have the function that uric acid is promoted to reduce.The present invention also provides the preparation method of the composition, which is to be mixed by the way that Poria cocos, semen coicis and pueraria lobata are cooked crushed after being dried with other components, to obtain the composition for being suitble to take.
Description
Technical field
The present invention relates to health product technology field more particularly to a kind of composition for promoting uric acid to reduce and its preparation sides
Method.
Background technique
Uric acid height is the substance of human body purine because metabolism gets muddled, cause uric acid in blood increase caused by a kind of generation
Thanking property disease is one kind of inferior health inducement.The inducement of high lithemia mostly feed if excessively drunk usually by overfeeding rich fatty diet
High protein, high sugar, high purine food and infection, overworked, spiritual sexual trauma and take some drugs etc.；Chinese medicine thinks
The insufficiency of the spleen with overabundance of dampness, wet turbid stasis blocking, be at a stop through tunnel and cause joint swelling and pain, when resin flux cream card.It is not only late adult onset in recent years,
And the trend of rejuvenation is had also appeared, at a kind of common disease.There are 1.2 hundred million people with high uric acid, industry in China according to incompletely statistics
Boundary is known as " the 4th is high " after " three high ".
Food external source and itself synthesize it is endogenous be uric acid two main sources, the former accounts for about 2/3rds, Hou Zhezhan
One third, the daily production quantity of internal uric acid and excretion are for an equilibrium state under normal circumstances.Uric acid is in blood
Highest solubility be 420 μm of ol/L, be more than this value, lithate is easily precipitated crystallizes and be deposited on tissue and cause inflammatory lesion,
Common harm is as follows:
1) can cause blood lipid hyperglycemia: hyperlipemia and hyperglycemia is that existing, uric acid height trouble is substantially synchronized with uric acid height
Person crowd occupies a large amount of ratios, this problem can be caused mainly because lithate compromises arterial endothelial cell, and pass through
Purine metabolism and other metabolic ways have promoted just this disease；
2) cause artery sclerosis: artery sclerosis is that more serious performance is substantially all when artery hardens
There can be the reaction of uric acid height.
3) gout is caused to break out: the high patient's long-term existence of uric acid, when a trigger point is contacted, body at first
Existing is exactly gouty attack,acute, is then transformed into chronic gout, then forms tophus.
4) to the influence of renal function: because most of uric acid will pass through kidney when giving off external, if
Excessive concentration, when hold-up is big, being certain to run well to kidney is affected, and may not see there is any table in early days
It is existing, by acting on for a long time, can occur kidney stone, renal necrosis, the pernicious reaction such as uronephrosis in succession.
It currently to the prevention and treatment cardinal principle of high lithemia is taken in by the oxygenolysis and purine of reduction nucleic acid in vivo.It is common
Pass through diet control and drug therapy (such as: Allopurinol)；The former is to dietetic requirement harshness, and the duration is long, and ordinary person is difficult to adhere to,
It works little；Medication amount deficiency may be selected in the latter, expensive, cannot be eaten for a long time, and have side effect to liver, kidney.
Summary of the invention
For overcome the deficiencies in the prior art, one of the objects of the present invention is to provide a kind of integration of drinking and medicinal herbs, can be used for generation
The composition for promoting uric acid to reduce of meal.The composition uses the natural materials of plant source for main ingredient, has low sugar, low
The characteristics of rouge, three that human body can be effectively reduced are high, promote internal ion metabolism balance and purine metabolism balance, promote excretion, with
Promote the reduction of uric acid.
The second object of the present invention is to provide the preparation method for the composition that above-mentioned promotion uric acid reduces.
An object of the present invention adopts the following technical scheme that realization:
A kind of composition for promoting uric acid to reduce, including following components by weight: 10-25 parts of Poria cocos, 10-25 parts
Semen coicis, 10-20 part pueraria lobata, the luxuriant Cilliums of 7-14 parts of circles, 8-16 part odd Asia seed powder, 0.5-3 parts of stripped tuna elastin laminins and
Supply 100 parts of auxiliary material.
Further, including following components by weight: 12-18 parts of Poria cocos, 15-20 parts of semen coicis, 13-17 portions of Pueraria lobotas
The luxuriant Cillium of root, 8-12 parts of circles, 7-10 parts of odd sub- seed powder, 1-2 parts of stripped tuna elastin laminins and the auxiliary material for supplying 100 parts.
Further, the auxiliary material is black tea powder, red date powder, purple sweet potato powder, whole milk powder, inulin, sodium bicarbonate and crystallization
One or more of fructose.
Further, the auxiliary material is by 12-14 parts of inulin, 0.8-1.0 parts of sodium bicarbonates, 7-8 portions of whole milk powders and 18-22
Part red date powder composition.
Further, the auxiliary material is made of 13-15 parts of inulin, 1-3 parts of black tea powders, 10-15 parts of crystal diabetins.
Further, the auxiliary material is by 18-20 parts of purple sweet potato powders, 6-8 portions of whole milk powders and 0.8-1.0 parts of sodium bicarbonate groups
At.
The second object of the present invention adopts the following technical scheme that realization:
A method of preparing the above-mentioned composition for promoting uric acid to reduce, comprising the following steps:
1) Poria cocos, semen coicis and pueraria lobata are cooked, it is dry to moisture≤5%, it crushes, sieving；
2) other components of formula ratio are taken, mixing machine are put into, in the revolving speed mixing 20-40min of 15-20rpm；
3) it dispenses, packaging.
Further, in step 1), using sterile autoclave after 0.1MPa pressure, 100-128 DEG C of wet steaming 20-30min
In 100-110 DEG C of heated-air drying to moisture≤5%.
Further, in step 1), using heated-air circulation oven in 120-165 DEG C of dry blowing to moisture≤5%.
Further, in step 2), in the revolving speed mixing 30min of 16rpm.
Compared with prior art, the beneficial effects of the present invention are:
The composition provided by the invention for promoting uric acid to reduce uses the natural materials of plant source for main ingredient, has
The characteristics of low sugar, low fat, three that human body can be effectively reduced are high, promote internal ion metabolism balance and purine metabolism balance, promote
Excretion, to promote the reduction of uric acid；
Pachymaran and triterpenoid in the composition promote the reduction of blood lipid and promote the balance of kalium ion and natrium ion；The heart of a lotus seed
The seed of jog's tears contains the vitamin B1 that can reduce uric acid level and adjusts the Job's tears element of the metabolic balance of adenine；Pueraria lobata pharmacological component
Clear cholesterol and triglyceride reduces gout symptom, reduces uric acid level；Circle bud Cillium and the offer of Qi Ya seed powder and enteron aisle
Dietary cellulosic with preferable compatibility reduces digestion waste in the residence time of human body, promotes the excretion of uric acid；Odd Asia seed
The omega-fatty acid of powder can inhibit the synthesis of endogenous uric acid, the compound raising human immunity of multivitamin, amino acid, minerals
Power；Stripped tuna elastin laminin can improve the accretion rate of purine, avoid building up, and inhibit hypoxanthine guanine phosphoribosyl synthesis transfer
The increase of enzyme, and then inhibit the synthesis of uric acid.The composition is from reducing blood pressure and blood lipoid and cholesterol, promote uric acid excretion, promote
Body ion metabolism balance acts on promoting a variety of aspect concertednesses such as purine metabolism balance, to combine the generation for inhibiting uric acid
With improve uric acid excretion, thus have the function that promote uric acid reduce.
In the preparation method of the composition provided by the invention, Poria cocos, semen coicis and the pueraria lobata three tastes ingredient are to pass through steaming
System and dry powder processed, and dietary fiber is provided the luxuriant Cillium of circle, odd sub- seed powder and provide the activity of oligopeptide at
Point or auxiliary material using what is directly mixed, can effectively improve human body to the absorptivity of the composition effective component and effectively
Ingredient plays a role degree in human body.
Specific embodiment
In the following, being described further in conjunction with specific embodiment to the present invention, it should be noted that is do not collided
Under the premise of, new embodiment can be formed between various embodiments described below or between each technical characteristic in any combination.
A kind of composition for promoting uric acid to reduce, including following components by weight: 10-25 parts of Poria cocos, 10-25 parts
Semen coicis, 10-20 part pueraria lobata, the luxuriant Cilliums of 7-14 parts of circles, 8-16 part odd Asia seed powder, 0.5-3 parts of stripped tuna elastin laminins,
15-40 parts of auxiliary materials.
Effective component in Poria cocos includes pachymaran and triterpene compound, and blood lipid is promoted to reduce and promote intracorporal
Kalium ion and natrium ion balance；
Said in Effective Formulas Tested by Physicians for Generations, coix lacryma-jobi congee controls long rheumatism numbness, reinforcing vital qi, also have consumer edema, long term usage make light of one's life by commiting suicide QI invigorating, belong to
Rheumatism numbness.It matches with the high lithemia insufficiency of the spleen with overabundance of dampness interpretation of the cause, onset and process of an illness；The key component of semen coicis includes vitamin B1With active constituent coix lacryma-jobi
Element, vitamin B1It is adjustable uric acid level to a certain extent, Coixol can inhibit actomyosin-adenosine triphosphate system,
Promote the metabolic balance of internal adenine；
Pueraria lobata has the function of that expelling wind and eliminating dampness, blood circulation, fragrance are amusing and detoxify, itself has no toxic side effect, and is treatment
Acute and chronic urarthritis and the good medicine of prevention gout breaking-out；Pueraria lobata pueraria isoflavone rich in, isoflavone glycoside and
The substances such as Triterpene saponins have the function of clearing gallbladder sterol, can reduce oily three rouge, can help to reduce gout symptom, reduce urine
Acid value；
Circle bud Cillium provides water-soluble dietary fiber abundant, inhibits to increase satiety, inhibits ascending, descending on blood glucose
Cholesterol；Moisture can be fully absorbed, agglomerate can extremely be drained by increasing volume, increase intestines peristalsis, when reduction excrement transports in the intestine
Between, and gradually become regular；
The dietary fiber that odd Asia seed powder provides includes water that is water-soluble and water-insoluble, providing with the luxuriant Cillium of circle
Soluble dietary fiber is cooperated, and intestines peristalsis and defecation are promoted, in addition, odd Asia seed powder also provides omega-fatty acid energy abundant
Effective hypoglycemic and blood lipid, to reduce the synthesis of endogenous uric acid；The compound raising people of multivitamin, amino acid, minerals
Body immunity；
Stripped tuna elastin laminin can increase purine bodies metabolic ferments HGPRT gene quantity, promote purine metabolism speed,
It avoids building up, has reached inhibition uricogenesis；It also can increase lactic dehydrogenase gene quantity simultaneously, promote cream
Acid decomposes, and reduces Lactate and reduces organic acid concentration in serum, to realize the effect for promoting uric acid excretion.This ingredient is long
Phase, which takes, to be softened, decompose the uric acid crystal and tubercle for having been formed in joint, to realize the effect of rehabilitation gout；
Stripped tuna elastin laminin can effectively inhibit the increase of hypoxanthine guanine phosphoribosyl synthesis transferase rich in dipeptides, and then inhibit uric acid
Synthesis.
The present invention also provides the preparation methods for the composition that the promotion uric acid reduces, comprising the following steps:
1) Poria cocos, semen coicis and pueraria lobata are cooked, it is dry to moisture≤5%, it crushes, sieving；
2) component of formula ratio is taken, mixing machine is put into, in the revolving speed mixing 20-40min of 15-20rpm；
3) it dispenses, packaging.
In this method, Poria cocos, semen coicis and three taste ingredient of pueraria lobata be by steaming and drying powder processed, and provide diet fibre
The luxuriant Cillium of the circle of dimension, odd sub- seed powder and the stripped tuna elastin laminin ingredient or auxiliary material for providing oligopeptide are using direct
Mixing, human body can be effectively improved and played a role in human body to the absorption of the composition effective component and effective component.
Embodiment 1:
A kind of composition for promoting uric acid to reduce, is made: 14.5 parts of Poria cocos, 14.5 parts of following components by weight
Semen coicis, 11.5 parts of pueraria lobatas, the luxuriant Cillium of 8.5 parts of circles, 8.5 parts of odd sub- seed powder, 1.5 parts of stripped tuna elastin laminins, 13 portions of chrysanthemums
Powder, 0.85 part of sodium bicarbonate, 7.5 portions of whole milk powders and the red date powder for supplying 100 parts；
Prepare the composition of promotion uric acid reduction, comprising the following steps:
1) Poria cocos, semen coicis and pueraria lobata are packed into sterile autoclave in 0.1MPa pressure, 120 DEG C of wet steaming 25min, taken out,
It in 105 DEG C of heated-air dryings to moisture≤5%, crushes, sieving；
2) other components of formula ratio are taken, mixing machine are put into, in the revolving speed mixing 30min of 16rpm；
3) it dispenses, packaging.
Embodiment 2:
A kind of composition for promoting uric acid to reduce, is made: 18 parts of Poria cocos, 18 portions of coix lacryma-jobi of following components by weight
Benevolence, 14.4 parts of pueraria lobatas, the luxuriant Cillium of 10.8 parts of circles, 8.8 parts of odd sub- seed powder, 2 parts of stripped tuna elastin laminins, 14 parts of inulin, 2 parts
Black tea powder and the crystal diabetin for supplying 100 parts；
Prepare the composition of promotion uric acid reduction, comprising the following steps:
1) Poria cocos, semen coicis and pueraria lobata are packed into sterile autoclave in 0.1MPa pressure, 115 DEG C of wet steaming 25min, taken out,
It in 105 DEG C of heated-air dryings to moisture≤5%, crushes, sieving；
2) other components of formula ratio are taken, mixing machine are put into, in the revolving speed mixing 30min of 16rpm；
3) it dispenses, packaging.
Embodiment 3:
A kind of composition for promoting uric acid to reduce, is made: 14.8 parts of Poria cocos, 14.8 parts of following components by weight
Semen coicis, 12 parts of pueraria lobatas, the luxuriant Cilliums of 8.6 parts of circles, 8.6 parts of odd sub- seed powder, 2 parts of stripped tuna elastin laminins, 12.9 parts of inulin,
7.4 part whole milk powder, 0.85 part of sodium bicarbonate and the purple sweet potato powder for supplying 100 parts；
Prepare the composition of promotion uric acid reduction, comprising the following steps:
1) Poria cocos, semen coicis and pueraria lobata are packed into heated-air circulation oven, in 140 DEG C of heated-air dryings to moisture≤5%, powder
It is broken, sieving；
2) other components of formula ratio are taken, mixing machine are put into, in the revolving speed mixing 30min of 16rpm；
3) it dispenses, packaging.
Embodiment 1-3 provide promote uric acid reduce composition, suggest packing specification be the every packet of 100g, it is proposed that
Amount 1 wraps every time 3 times a day to be adult, and converting into dosage is 5g/kg.bw/day.Embodiment 1-3 provides 3 kinds of different tastes
Promote uric acid reduce composition.
Performance detection and effect assessment
Taking weight is the male rat of the SD of 200 ± 10g, the feed of 10% yeast powder, 0.1% adenine is added
It feeds 7 days, as adaptation；Rat is grouped at random, is divided into 7 groups, every group 11.
Daily feedstuff feeding amount is 100g/kg.bw/day, and using allopurinol as positive control, mixing appetite is
0.5wt%, blank control group diet, the composition and feed that the first test group is reduced using the promotion uric acid of embodiment 1
The weight ratio feeding of 1:9, the second test group is using the composition for promoting uric acid to reduce of embodiment 2 and the weight ratio of feed 1:9
Feeding, third test group is using the composition for promoting uric acid to reduce of embodiment 3 and the weight ratio feeding of feed 1:9, the 4th examination
A group weight ratio feeding for the composition for promoting uric acid to reduce and feed 1:1 that provide using embodiment 1 is tested, the 5th test group uses
The weight ratio feeding of the composition for promoting uric acid to reduce and feed 1:99 that embodiment 1 provides, normally feeds after feeding 30 days.
Respectively in on-test D0, the 7th day D7, off-test D30 and 14 days D37 of end, using HPLC usable floor area
Normalization method analyzes the content of uric acid in serum, as a result as shown in the table.
Influence [μm ol/L] of 1 composition of table to uric acid content
| Group | D0 | D7 | D30 | D44 |
| Positive controls | 79.54±7.93 | 46.33±5.29 | 43.09±5.34 | 66.09±11.76 |
| Blank control group | 78.26±8.11 | 78.93±8.46 | 78.86±8.20 | 78.43±9.72 |
| First test group | 78.69±8.74 | 52.78±6.28 | 51.56±6.17 | 56.19±7.54 |
| Second test group | 79.92±8.82 | 52.63±6.15 | 51.43±6.06 | 57.76±8.06 |
| Third test group | 79.85±8.09 | 52.41±6.03 | 51.38±6.37 | 57.53±8.37 |
| 4th test group | 79.26±8.34 | 48.57±6.08 | 46.19±6.79 | 56.22±7.21 |
| 5th test group | 79.57±8.63 | 54.31±6.60 | 54.04±6.92 | 59.02±7.81 |
As seen from the above table, the composition for promoting uric acid to reduce obtained by the present embodiment 1-3, the 7th day carried out in test,
First recommends edible dosage to third test group with 2 times, and the increase of the content of uric acid in rat blood serum can be effectively suppressed, inhibit effect
Fruit is inferior to positive controls, but has significant difference relative to blank control group；The 4th test group of high dose group and the positive are right
Suitable according to group effect, low dose of reason group is relative to blank test group and has significant difference.At the 30th day of test, positive control
The inhibitory effect of group is declined and the inhibitory effect of the test group of the present embodiment 1-3 increases.After administration stops, sun
The uric acid level rebound significantly of property control group, and the uric acid level of test group is relatively stable.
In conclusion the composition provided by the present application for promoting uric acid to reduce has the preferable effect for inhibiting uric acid climbing power
Fruit, while drug resistance or drug dependence are not generated.
The above embodiment is only the preferred embodiment of the present invention, and the scope of protection of the present invention is not limited thereto,
The variation and replacement for any unsubstantiality that those skilled in the art is done on the basis of the present invention belong to institute of the present invention
Claimed range.
Claims (10)
1. a kind of composition for promoting uric acid to reduce, which is characterized in that including following components by weight: 10-25 parts of Fu
Siberian cocklebur, 10-25 part semen coicis, 10-20 parts of pueraria lobatas, the luxuriant Cillium of 7-14 parts of circles, 8-16 portions of odd sub- seed powder, 0.5-3 portions of stripped tunas
Elastin laminin and the auxiliary material for supplying 100 parts.
2. the composition for promoting uric acid to reduce as described in claim 1, which is characterized in that including by weight with the following group
Point: 12-18 part Poria cocos, 15-20 part semen coicis, 13-17 part pueraria lobatas, 8-12 part round bud Cilliums, 7-10 parts of surprise Asia seed powder,
1-2 parts of stripped tuna elastin laminins and the auxiliary material for supplying 100 parts.
3. the composition for promoting uric acid to reduce as described in claim 1, which is characterized in that the auxiliary material is black tea powder, jujube
One or more of powder, purple sweet potato powder, whole milk powder, inulin, sodium bicarbonate and crystal diabetin.
4. as claimed in claim 3 promote uric acid reduce composition, which is characterized in that the auxiliary material by 12-14 parts of inulin,
0.8-1.0 parts of sodium bicarbonates, 7-8 portions of whole milk powders and 18-22 parts of red date powder compositions.
5. as claimed in claim 3 promote uric acid reduce composition, which is characterized in that the auxiliary material by 13-15 parts of inulin,
1-3 parts of black tea powders, 10-15 parts of crystal diabetin compositions.
6. the composition for promoting uric acid to reduce as claimed in claim 3, which is characterized in that the auxiliary material is by 18-20 parts of purple sweet potatos
Powder, 6-8 portion whole milk powder and 0.8-1.0 parts of sodium bicarbonate compositions.
7. a kind of method for preparing the composition that promotion uric acid as claimed in any one of claims 1 to 6 reduces, which is characterized in that
The following steps are included:
1) Poria cocos, semen coicis and pueraria lobata are cooked, it is dry to moisture≤5%, it crushes, sieving；
2) other components of formula ratio are taken, mixing machine are put into, in the revolving speed mixing 20-40min of 15-20rpm；
3) it dispenses, packaging.
8. the method for claim 7, which is characterized in that in step 1), using sterile autoclave in 0.1MPa pressure,
In 100-110 DEG C of heated-air drying to moisture≤5% after 100-128 DEG C of wet steaming 20-30min.
9. the method for claim 7, which is characterized in that dry in 120-165 DEG C using heated-air circulation oven in step 1)
It steams to moisture≤5%.
10. the method for claim 7, which is characterized in that in step 2), in the revolving speed mixing 30min of 16rpm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811300601.9A CN109329930A (en) | 2018-11-02 | 2018-11-02 | A kind of composition and preparation method thereof for promoting uric acid to reduce |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811300601.9A CN109329930A (en) | 2018-11-02 | 2018-11-02 | A kind of composition and preparation method thereof for promoting uric acid to reduce |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109329930A true CN109329930A (en) | 2019-02-15 |
Family
ID=65313140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811300601.9A Pending CN109329930A (en) | 2018-11-02 | 2018-11-02 | A kind of composition and preparation method thereof for promoting uric acid to reduce |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109329930A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111134329A (en) * | 2018-11-06 | 2020-05-12 | 深圳华大生命科学研究院 | Application of plant polysaccharide in preparation of intestinal type-related hyperuricemia drug |
| CN112825946A (en) * | 2021-03-05 | 2021-05-25 | 山西康寿茶业有限公司 | Formula and preparation method of acid clearing tea |
| CN113287649A (en) * | 2021-03-10 | 2021-08-24 | 咀香园健康食品（中山）有限公司 | Composition with function of reducing uric acid and honey-suckle fruit polypeptide biscuit |
| CN113456741A (en) * | 2021-07-21 | 2021-10-01 | 武汉英纽林生物科技有限公司 | Composition for preventing hyperuricemia and preparation method thereof |
| CN114010755A (en) * | 2021-12-15 | 2022-02-08 | 本元大健康科技产业(广东)有限公司 | Preparation for controlling uric acid and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125067A (en) * | 1995-03-03 | 1996-06-26 | 熊显耀 | Multifunctional health-care food nd its processing method |
| CN105999217A (en) * | 2016-06-22 | 2016-10-12 | 深圳市老年医学研究所 | Composition for preventing and treating hyperuricemia as well as preparation method and application of composition |
| CN106616177A (en) * | 2016-11-28 | 2017-05-10 | 广东中顺华功生物科技有限公司 | Composite polypeptide solid beverage with curative effect of decreasing uric acid, and preparation method of composite polypeptide solid beverage |
| CN106805234A (en) * | 2016-12-19 | 2017-06-09 | 江苏红瑞制药有限公司 | A kind of anti-trioxypurine food compositions |
| CN107753801A (en) * | 2017-12-06 | 2018-03-06 | 周勇 | Anti-trioxypurine, drop purine treat pharmaceutical composition of gout and preparation method thereof |
| CN108402460A (en) * | 2018-05-11 | 2018-08-17 | 中国医科大学 | A kind of multifunctional food composition and preparation method thereof increasing bone density |
-
2018
- 2018-11-02 CN CN201811300601.9A patent/CN109329930A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125067A (en) * | 1995-03-03 | 1996-06-26 | 熊显耀 | Multifunctional health-care food nd its processing method |
| CN105999217A (en) * | 2016-06-22 | 2016-10-12 | 深圳市老年医学研究所 | Composition for preventing and treating hyperuricemia as well as preparation method and application of composition |
| CN106616177A (en) * | 2016-11-28 | 2017-05-10 | 广东中顺华功生物科技有限公司 | Composite polypeptide solid beverage with curative effect of decreasing uric acid, and preparation method of composite polypeptide solid beverage |
| CN106805234A (en) * | 2016-12-19 | 2017-06-09 | 江苏红瑞制药有限公司 | A kind of anti-trioxypurine food compositions |
| CN107753801A (en) * | 2017-12-06 | 2018-03-06 | 周勇 | Anti-trioxypurine, drop purine treat pharmaceutical composition of gout and preparation method thereof |
| CN108402460A (en) * | 2018-05-11 | 2018-08-17 | 中国医科大学 | A kind of multifunctional food composition and preparation method thereof increasing bone density |
Non-Patent Citations (3)
| Title |
|---|
| 常映明等: "《抗衰老漫谈 点燃生日蛋糕上的第120根蜡烛》", 30 November 2017 * |
| 张雅莉等: "强化膳食纤维饮食干预对肥胖合并高尿酸血症患者的影响", 《中国老年学杂志》 * |
| 齐玉梅等: "《特殊医学用途配方食品 临床应用参考目录》", 31 August 2017 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111134329A (en) * | 2018-11-06 | 2020-05-12 | 深圳华大生命科学研究院 | Application of plant polysaccharide in preparation of intestinal type-related hyperuricemia drug |
| CN112825946A (en) * | 2021-03-05 | 2021-05-25 | 山西康寿茶业有限公司 | Formula and preparation method of acid clearing tea |
| CN113287649A (en) * | 2021-03-10 | 2021-08-24 | 咀香园健康食品（中山）有限公司 | Composition with function of reducing uric acid and honey-suckle fruit polypeptide biscuit |
| CN113456741A (en) * | 2021-07-21 | 2021-10-01 | 武汉英纽林生物科技有限公司 | Composition for preventing hyperuricemia and preparation method thereof |
| CN114010755A (en) * | 2021-12-15 | 2022-02-08 | 本元大健康科技产业(广东)有限公司 | Preparation for controlling uric acid and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109329930A (en) | A kind of composition and preparation method thereof for promoting uric acid to reduce | |
| CN101473953B (en) | Fabricated food for cleaning blood and expelling toxin as well as method for processing the same and application | |
| CN104643250B (en) | It is a kind of can bidirectional modulation body weight improve inferior health solid beverage | |
| KR101738912B1 (en) | Composition For Anti-obesity And Diet | |
| CN102366093A (en) | Composite slimming health food | |
| CN110771880A (en) | Blood sugar-reducing quinoa meal replacement powder and preparation process thereof | |
| CN104856003A (en) | Non-full nutritional formula food for patients with diabetes | |
| CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN108391785A (en) | A kind of functionality meal replacement powder and its manufacture craft and application | |
| CN104855994A (en) | Non-full nutritional formula food for patients with nephropathy | |
| CN102090563B (en) | Relaxing and sleeping health-care food and preparation method thereof | |
| CN107198246A (en) | A kind of health composition and a kind of health care preparation | |
| CN101564160B (en) | Food for preventing and treating hyperlipemia and hyperglycemia and preparation method thereof | |
| CN111771988A (en) | Nutritional food suitable for diabetic patients and preparation method thereof | |
| CN106418501A (en) | Healthcare food with weight reducing function | |
| CN102204649A (en) | Healthcare food for regulating and stabilizing blood sugar and method for preparing same | |
| CN105533446A (en) | Nutritious oatmeal with health-care effect and preparation method thereof | |
| CN104856000A (en) | Non-complete-nutrition formula food for insomnia | |
| CN104839698A (en) | Cardiovascular disease non-total nutrient formula food | |
| CN102511876B (en) | Hawthorn red jujube thick syrup and production process thereof | |
| CN108175004A (en) | It is a kind of suitable for beverage of diabetic and preparation method thereof | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN105050427A (en) | Edible composition, food product comprising same, and preparation method for the food product | |
| CN102640893B (en) | Black malt and whole herb composite nutrient and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190215 |
|
| RJ01 | Rejection of invention patent application after publication |